Literature DB >> 8905723

NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia.

C Humphries1, A Mortimer, S Hirsch, J de Belleroche.   

Abstract

We investigated the expression of the N-methyl-D-aspartate (NMDA) receptor, an important glutamate receptor, in brains from a population of well characterized schizophrenic patients who prospectively consented to tissue donation. Levels of NR-1 mRNA in tissue homogenates of superior temporal cortex were reduced by 30% in cognitively impaired schizophrenic patients compared with controls (p < 0.04), while levels in patients without cognitive impairment showed no such reduction. The NR-1 mRNA deficit was significantly correlated with general cognitive function as rated with the Global Deterioration scale (p < 0.001), the Mini-Mental State examination (p < 0.01) and the premorbid IQ determined using the National Adult Reading Test (NART, p < 0.01). NR-1 mRNA concentration was not correlated with age, sex, pH or postmortem delay in the control and schizophrenia group when analysed separately or combined. There was, therefore, a significant correlation between NR-1 mRNA loss and cognitive deterioration in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8905723     DOI: 10.1097/00001756-199608120-00040

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  27 in total

Review 1.  Functional genomics and psychiatric illness.

Authors:  Wendy Hasenkamp; Scott E Hemby
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

Review 2.  The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.

Authors:  Wei Hu; Matthew L MacDonald; Daniel E Elswick; Robert A Sweet
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

3.  Altered NMDA receptor expression and behavior following postnatal hypoxia: potential relevance to schizophrenia.

Authors:  A Schmitt; M Fendt; M Zink; U Ebert; M Starke; M Berthold; A Herb; G Petroianu; P Falkai; F A Henn
Journal:  J Neural Transm (Vienna)       Date:  2006-10-23       Impact factor: 3.575

4.  Decreased numerical density of kainate receptor-positive neurons in the orbitofrontal cortex of chronic schizophrenics.

Authors:  L J Garey; K A Von Bussmann; S R Hirsch
Journal:  Exp Brain Res       Date:  2006-02-28       Impact factor: 1.972

Review 5.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

6.  Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: postmortem study.

Authors:  Monika Vrajová; Frantisek Stastný; Jirí Horácek; Jan Lochman; Omar Serý; Sona Peková; Jan Klaschka; Cyril Höschl
Journal:  Neurochem Res       Date:  2010-03-05       Impact factor: 3.996

7.  Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia.

Authors:  Amy E Steffek; Robert E McCullumsmith; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2008-06-17       Impact factor: 4.939

8.  The biochemical womb of schizophrenia: A review.

Authors:  N Gaur; S Gautam; M Gaur; P Sharma; G Dadheech; S Mishra
Journal:  Indian J Clin Biochem       Date:  2008-12-20

9.  Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine.

Authors:  K S Alexander; A Pocivavsek; H-Q Wu; M L Pershing; R Schwarcz; J P Bruno
Journal:  Neuroscience       Date:  2013-02-06       Impact factor: 3.590

10.  Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia.

Authors:  L J Garey; W Y Ong; T S Patel; M Kanani; A Davis; A M Mortimer; T R Barnes; S R Hirsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-10       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.